News

Read the latest news about LamKap Bio Group

Written on Monday, 13 May 2024

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Written on Friday, 10 May 2024

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody

Written on Wednesday, 08 May 2024

A novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Written on Thursday, 27 April 2023

LamKap Bio presented data on NILK-2301, NILK-2401 & NILK-3301

Written on Friday, 02 September 2022

SITC 37th Annual Meeting 2022

Written on Wednesday, 10 August 2022

APASL Oncology 2022 Meeting

Written on Monday, 08 August 2022

ESMO Congress 2022

Written on Friday, 18 September 2020

LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment.